Indeed, AR treatment reduced STAT3 nuclear localization and lowered the expression levels of STAT3 targeted Bcl-xL and Mcl-1 that are involved in CRC cell proliferation and survival (Lassmann et al., 2007; Abdulghani et al., 2013), and MMP-2 that is involved in CRC cell mobility (Liu et al., 2015; Ye et al., 2017). This evidence concerns the gene AR and colorectal carcinoma.